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Abstract
Background: Primary hepatocellular carcinoma (PHC) is one of the most common cancers in
Zimbabwe. Hepatitis B virus (HBV) and hepatitis C virus (HCV) are suspected to play a major role
in causing this cancer. The objective of this study was to determine the seroprevalence of HBV and
HCV in PHC at Parirenyatwa Referral Hospital in Zimbabwe. We evaluated the serological markers
of the two viruses in patients with PHC using commercially available enzyme-linked
immunosorbent kits.
Results: Out of the 60 patients with PHC, 48.3% were seropositive for HBV and 20.0% were
seropositive for HCV. Co-infection by HCV and HBV was found in 8% of the patients. Only 13.3%
of the health controls (blood donors) were positive for HBV. All the controls were negative for
HCV.
Conclusion: The high seropositivity of HBV and HCV in PHC in Zimbabwe suggested that the
two viruses were a major cause of the cancer.
Background
Liver cancer is one of the most common cancers in Zim-
babwe and Africa [1,2]. Hepatitis B virus (HBV) and hep-
atitis C virus (HCV) are suspected to play an important
aetiological role in liver cancer in this region and the con-
tinent. HBV is a partially double-stranded DNA virus and
is an important cause of morbidity and mortality world-
wide [3,4]. Globally, it is estimated that about 2 billion
people have been infected with HBV and about 350 mil-
lion people are chronically infected [5]. Most of the
chronically-infected people are found in developing
countries and are at a high-risk of developing liver cirrho-
sis and hepatocellular carcinoma [6,7]. Areas with high
prevalence of HBV include Southeast Asia, China and
Africa, where approximately 10% of the population are
chronic carriers [5,8]. In persons infected with HBV, mor-
bidity and mortality result when inflammatory liver dis-
ease progresses to cirrhosis and primary hepatocellular
carcinoma [8]. High-risk groups of HBV infection include
intravenous drug users, attendees of sexually transmitted
disease clinics, homosexual men, patients undergoing
haemodialysis, children born to mothers who are hepati-
tis B surface antigen positive and health care workers
[6,7,9].
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HCV is a positive-stranded RNA virus which belongs to
the Flaviviridae family [10]. Worldwide, the virus infects
about 170 million people [11]. Infection by this virus can
be resolved spontaneously in only about 15-20% of cases
and chronic infection is established in the remaining 80-
85% [12]. Most of these chronic HCV infections usually
lead to severe hepatitis, liver cirrhosis and hepatocellular
carcinoma [13-17]. The risk of developing PHC ranges
from 1-5% after about two decades of chronic infection
[18]. HCV infection usually occurs following direct
parenteral exposure to contaminated body fluids, espe-
cially blood [16,19]. The prevalence of both HBV and
HCV in PHC in Zimbabwe is poorly known. It was against
this background that we set out to evaluate the presence of
antibodies to HBV surface antigen and HCV in patients
with PHC at Parirenyatwa Central Hospital in Zimbabwe.
Results
Patient data
Data from hospital records showed that all the patients
presented with abdominal distending discomfort, charac-
terised by right upper quadrant pain and hepatic mass
enlargement in some cases. Weight loss was observed in
all the patients with almost a third showing that they were
jaundiced. Ascites and fever symptoms were not uncom-
mon in the patients on presentation or during hospitalisa-
tion. All the patients had impaired liver function in one or
more of serum aminotransferases, prolonged pro-
thrombin time and albumin levels. Out of the 60 patients,
53 (88%) had serum gamma-glutamyl transferase (GGT)
levels above the reference range, with 10 of them having
GGT values greater than 200 IU/L. Of all the patients, 30
(50%) had alanine transaminase (ALT) levels elevated
above the upper limit of normal range. The age ranges of
patients and controls are given in Table 1.
The clinical management of the patients was also assessed
from the records. Most of the patients were of poor social
background, either in the lowest income group or not
employed at all. Some of the males (n = 11) over 30 years
of age had a history of alcohol drinking. Of all the
patients, 7 (12%) had cirrhosis clearly indicated in their
records. Alpha-fetoprotein (AFP) levels were greater than
400 ng/ml in 33 patients (55%) and 21 patients (35%)
with AFPs less than 400 ng/ml had confirmation of PHC
by ultrasound and cytology. The difference in age distribu-
tion in PHC patients and health individual controls was
not significant (p > 0.05). The difference in sex between
the two groups was also not significantly different (p >
0.05).
HBsAg and HCV antibody status in PHC patients
The seroprevalence of HBV and HCV in patients with PHC
and health blood donours is summarized in Table 2. Of
the 60 PHC cases, 29 patients (48%) were positive for
HBsAg of which 7 were females and 22 were males. The
age range of patients was 18-70 years and the mean was
43.8 years. Only 10 (34%) of the patients were over 45
years of age. The mean age of HBsAg negative patients was
47.6 years. There was no significant discrepancy between
the mean ages of HBsAg positive and negative patients.
Only 4 control subjects were positive for HBsAg. The rela-
tive risk for developing PHC in patients with HBsAg was
high when control subjects were considered as a reference
group (odds ratio = 1.62, 95% CI 0.69-1.64).
A total of 12 (20%) PHC patients were positive for anti-
HCV and 8 (67%) of these patients were over 45 years of
age (66.7%) and the other remaining 4 (33%) were below
45 years. All the control patients from blood donors were
negative for anti-HCV antibodies. The difference in males
and females infected with HCV was not significant (p >
0.05). The mean age of patients who were positive for
anti-HCV was 51.26 years and the age range was 16-70
years. The odds ratio or relative risk for the development
of PHC in anti-HCV positive patients could not be ascer-
tained because none of the control individuals was posi-
tive and the calculation required an integer for the
reference sample. Of the 12 patients who were anti-HCV-
positive, 4 had AFP levels greater than 400 ng/ml whilst
two had their AFP levels within the normal range (0-10
ng/ml). The prevalence of HBsAg was significantly higher
than that of anti- HCV both in PHC patients and controls
(p < 0.05). The presence of both anti-HCV and HBsAg was
noted in 5 patients. It was also noted that more than half
of the patients had infection with HBV and/or HCV.
The relative risk of developing PHC was strongly associ-
ated with HBV infection. The unadjusted odds ratio for
PHC development was high (1.615; 95% CI 0.69 - 1.65)
for overall HBV infection. For those patients with HBsAg
alone, the risk for PHC development, using the cases
which were negative for HBsAg as a reference group and
healthy individuals as controls, was still high (odds ratio
Table 1: Sex and age parameters for PHC patients and health controls
Parameter PHC patients (n = 60) Health Controls (n = 30)
Age range 16 - 81 years 16 - 69 years
Mean age 45.7 years 38.5 years
Male to Female ratio 2:1 2.08:1Infectious Agents and Cancer 2009, 4:15 http://www.infectagentscancer.com/content/4/1/15
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= 1.48: 95% CI 0.81-1.53). The relative risk for PHC devel-
oping in dual infection with HCV using non-HBsAg cases
as references and healthy individuals as controls, was low
(odds ratio = 0.818). The odds ratio in patients positive
for either anti-HCV and HBsAg or both was even higher
(odds ratio = 1.875; 95% CI 0.54 - 1.88).
Discussion
Parirenyatwa Hospital is a supra-referral hospital in Zim-
babwe. Patients suspected to have primary hepatocellular
carcinoma are referred from primary hospitals and clinics
around the country to this referral hospital. Therefore,
although our study had only 60 PHC patients, they were
likely to be representative of the whole country. This study
strongly suggested that Hepatitis B and C viruses were
important etiological factors of PHC in Zimbabwe.
Although other factors such as exposure to aflatoxins
(from mouldy grains and cereals) and alcohol consump-
tion were believed to be important, hospital records for
most of the patients lacked the information. Alcohol con-
sumption was documented in only 20% of the patients.
Information on risks to HBV and HCV infection such as
history of blood transfusion, use of intravenous drug
abuse and traditional surgical procedures could also not
be obtained from the files. These parameters could have
some influence on the prevalence of seropositivity of PHC
patients to HBV and HCV. Aminotrasferase levels were
assessed in the records and most patients had abnormal
levels of one or more of ALT, AST and GGT being elevated.
This is in agreement with studies that showed extensive
hepatocellular damage in PHC patients [20-23]. All the
patients who were positive for anti-HCV and HBsAg had
elevated hepatic enzymes. Albumin was low and pro-
thrombin time was prolonged in most of the cases.
Hepatic aminotransferases were not measured in the con-
trols to evaluate hepatocyte damage in those who were
HBsAg-positive. There is a strong link between HCV and
cirrhosis with 60-80% of HCV-positive PHC patients
being cirrhotic [24-26]. It could have been interesting to
note this association in cirrhotic HCV positive PHC cases.
Only seven of the patients whose cirrhotic condition was
well documented were in the study and anti-HCV anti-
bodies were only found in two patients who also had
HBsAg in their sera. The cirrhotic condition of other
patients could not be established and hence an associa-
tion with HCV could not be studied. The biopsy rate is low
due to poor prognosis and late presentation. Only 6
patients had histologically verified PHC status. The diag-
nosis of PHC based on biochemical evaluation of AFP is
controversial especially when levels less than 400 ng/ml
are encountered. AFP levels were greater than 400 ng/ml
in 33 patients, six had histological proof and the remain-
der were confirmed by cytology and ultrasound scanning
when focal or multifocal lesions were suggested. The diag-
nosis techniques employed were convincing that the cases
certainly had PHC.
The risks of acquiring HBV and HCV infection could not
be assessed for this study. The detection of viral markers
in two female teenagers with PHC suggested that they
could have acquired the viruses parenterally or vertically.
In previous studies of PHC, anti-HCV and HBsAg have
been found in even younger patients of 16 years by biopsy
[20,27]. The mean age of PHC patients of 45.7 years in
our study agreed well with those found in studies in South
Africa (45 years), Nigeria (46.7 years) and Southern Africa
(44.8 years) [20,23,27]. In Mozambique the mean age in
Shangaan ethnic group was 33.4 years and 50% of the
patients were below 30 years [21].
The presence of antibodies to the HBsAg in some of the
PHC patients clearly indicated HBV infection. The pres-
ence of HBsAg is normally used as a diagnostic marker to
indicate acute or chronic infection [28]. It could have
been interesting if we had also looked at the presence of
HBV DNA in the samples. However, in highly endemic
areas, HBV DNA has also been detected in blood or liver
of patients without HBsAg [29]. The diagnosis of HBV by
detection of HBsAg is very reliable only in acute phase
infection and present infection [27,30]. It is not indicative
of past infection. However most of the PHC studies done
showed that HBsAg is expressed in 70-80% of HBV posi-
tive patients who were found to be positive for viral DNA
[30,31]. The reliability of HBsAg as a marker of HBV infec-
tion in PHC is based on the expression of this antigen
from the integrated viral genome in the hepatocyte DNA
during vigorous active hepatocyte proliferation and turn-
over. At least 80% of HBsAg carriers have evidence of
Table 2: Seropositivity and negativity for Anti-HCV and HBsAg in PHC and health blood donors
Parameter PHC (n = 60) Control s (n = 30) p value
Anti-HCV positivity 12 (20%) 0 (0%) <0.05
Anti-HCV negativity 48 (80% 30 (100%) <0.05
HBsAg positivity 29 (48.3%) 4 (13.3%) <0.05
HBsAg negativity 31 (51.7%) 26 (86.7%) <0.05
Dual anti-HCV & HBsAg positivity 5 (8.3%) 0 (0%) -
Anti-HCV and/or HBsAg positivity 36 (60%) 4 (13.3%) -
Anti-HCV and/or HBsAg negativity 24 (40%) 26 (86.7%) -Infectious Agents and Cancer 2009, 4:15 http://www.infectagentscancer.com/content/4/1/15
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chromosomal integration of viral sequences, by Southern
hydridisation of tumour DNA [31,32]. Other markers that
show past infection could have been assayed for to evalu-
ate overall exposure. Our results confirmed previous
reports of high prevalence of HBsAg in patients with PHC
in sub-Sahara Africa, especially the southern parts
[20,27,33].
The presence of antibodies to HCV in some of the patients
also suggested that the virus was also an important aetio-
logical agent in PHC in Zimbabwe. It was not clear
whether some of the patients with anti-HCV had already
resolved the virus. The resolution of HCV infection occurs
in 15-20% of patients [12,34]. It could have been an inter-
esting study if we had also looked at the presence of HCV
RNA in the samples. However, it takes between a decade
and three for the development of PHC from time of infec-
tion with HCV and the viral RNA may disappear upon res-
olution but the antibodies persist [35,36]. Detection of
viraemia by polymerase chain reaction (PCR) could also
have been done to detect cases where there was active viral
replication.
In our study, 48.3% of 60 PHC patients were HBsAg pos-
itive and 20% were anti-HCV positive. In a previous study
in Zimbabwe, HBsAg was detected in 42.6% of the PHC
patients of the 62 patients studied [33]. Positivity for anti-
HCV was in 23.8% using a lesser sensitive and specific sec-
ond generation assay [33]. The two studies show that HBV
remains the major infection of hepatitis viruses in the
region. The prevalence of HBsAg in controls (13.3%) was
less than the prevalence of 24.2% observed in a study of
660 health individuals [37,38]. This probably was due to
the smaller proportion of the present study group (30
blood donors). The observation of no anti-HCV positive
cases in controls is agreement with data from the National
Blood Transfusion Service which show a prevalence of less
than 1% in healthy blood donors. However, another
study in Zimbabwe has observed an anti-HCV seropositiv-
ity of 8% in healthy rural individuals [22]. Co-infection
by HCV and HBV was found in this study. Although HBV
and HCV may be independent risk factors of PHC, dual
infection is likely to increase the risk of primary hepatocel-
lular carcinogenesis. Some studies have also reported dual
infection by HBV and HCV in PHC [20,23,30]. However,
the absence of serological markers for either HBV and/or
HCV in PHC in some PHC patients could not rule out the
role of the two viruses in carcinogenesis. Studies have
shown that hepatic tissues could have viral genomic
sequences in one-third or more of the serologically nega-
tive subjects [38]. It was also suspected that aflatoxin con-
tamination could also have played a significant role in
PHC development since Zimbabwe has been found to
have this post-harvest problem [39]. This study and previ-
ous ones, therefore, demonstrate that HBV and HCV are
important factors in chronic liver disease and subse-
quently PHC development in Southern Africa.
Conclusion
HBV and HCV play a significant role in the aetiology of
hepatocellular carcinoma in Zimbabwe.
Patients and Methods
Study subjects
The sixty patients were presented to Parirenyatwa Hospital
between October 1999 and August 2000 and were diag-
nosed as having PHC. Sera for the patients were collected
from the Radioimmunoassay (RIA) Laboratory of the
Public Health Laboratory (PHL). The serum samples were
collected after determination of the levels of the tumour
marker, Alpha-fetoprotein (AFP). The sera were stored at -
20°C until assayed for anti-HCV antibodies and HBsAg.
The medical records of the patients were also examined
for diagnostic tests and evaluations suggesting or confirm-
ing primary hepatocellular carcinoma. The tests included
ultrasound scanning, X-ray photography, needle aspirate
cytological proof and liver biopsy histology. Of the 60
patients recruited in this study, only 6 had liver biopsy
evaluation of PHC by histological examination. The rest
of the patients' diagnosis depended on ultrasound scan-
ning, cytology (fine needle aspirate), clinical features and
biochemical evaluations of liver functions and AFP levels.
Data on age and sex were also extracted. Controls (health
blood donors) (n = 30) were included in the study. They
were mainly health blood donors from the National
Blood Transfusion Services.
Laboratory tests of anti-HCV and anti-HBV serological 
markers
All samples (patients and controls) were tested for the
anti-HCV using the commercially available MUREX anti-
HCV (Version 4.0) kit (Abbott Diagnostic Division, RSA)
according to manufacturer's instructions. The MUREX
anti-HCV (Version 4.0) is a third generation solid phase
enzyme immunoassay in which a mixture of highly puri-
fied viral antigens is coated into microwells of a microtitre
plate. The antigens contain sequences from the core
(Structural), NS3 protease/helicase (non-structural), NS4
(non-structural) and the NS5 replicase (non-structural)
regions of HCV. During incubation with samples any anti-
HCV antibodies present in the sample will bind to the
immobilized antigens. Following washing to remove
unbound material, the captured anti-HCV antibodies are
incubated with peroxidase conjungated monoclonal anti-
human IgG. The conjugate will bind to the immobilized
anti-HCV through the anti-human IgG moiety. After
removal of excess conjugate, bound enzyme is detected by
the addition of a solution containing 3,3;5,5- tetramethyl
benzidine (TMB) and hydrogen peroxide. The enzyme
peroxidase changes the substrate to a purple colour in theInfectious Agents and Cancer 2009, 4:15 http://www.infectagentscancer.com/content/4/1/15
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wells, which contain anti-HCV positive samples. The
enzymatic reaction is terminated with sulphuric acid to
give an orange colour that is read spectrophotometrically.
The amount of conjugate bound and hence colour in the
wells, is directly proportional to the concentration of anti-
bodies to HCV in the specimen.
All the samples were also tested for HBsAg using the Bioe-
lisa Kit (Biokit, RSA) according to manufacturer's instruc-
tions. The Bioelisa Kit is an ELISA test kit for the detection
of the hepatitis B surface antigen (HBsAg) in human sera
or plasma. The bioelisa HBsAg assay is a direct immu-
noenzymatic method of the "sandwich" type in which
guinea pig anti-HBs antibodies coated onto microtitre
plate wells act as the capture antibody and goat anti-HBs
anti-bodies marked with peroxidase serve as conjugate
antibodies. During the test procedure, the sample to be
analysed is incubated in one of the antibody coated wells.
If the sample contains HBsAg, the antigen will bind to the
antibody on the plate. After washing to eliminate any
unbound material, goat anti-HBs conjugate is added to
the well and allowed to react with the antigen-antibody
complex formed in the first incubation. After a second
incubation and subsequent washing, an enzyme substrate
solution containing a chromogen (TMB) is added. This
solution will develop a blue colour if the sample is HBsAg
positive. The blue colour changes to yellow after blocking
with sulphuric acid and can be read spectrophotometri-
cally. The intensity of the colour is proportional to the
amount of HBsAg in the test specimens.
The results were analysed. Continuous variables were
compared using the Student's t-test. Categorical data were
compared using the Pearson's Chi-squared test or Fisher's
exact test. P-values < 0.05 were considered statistically sig-
nificant. Statistical analyses were performed using the Epi-
info program, version 2000 package.
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